Rx&D commends Ontario Government's Efforts to Protect the Safety and Integrity of the Drug System



    TORONTO, April 27 /CNW Telbec/ - The following is a statement by Russell
Williams, President of Canada's Research-Based Pharmaceutical Companies (Rx&D)
reacting to the Ontario Government's announcement that it is taking action to
curtail a "drug recycling" scheme allegedly involving rebates by generic drug
makers.
    "Canada's Research-Based Pharmaceutical Companies (Rx&D) commends the
Ontario Government for taking bold action to protect the integrity and safety
of the drug system in Ontario and the interests of taxpayers.
    "Patients in Ontario need to know that the system is safe and transparent
and that they are getting fair value for their medicines. The actions taken by
the Executive Officer of Ontario Public Drug Programs will ensure confidence
and trust in the system and that tax dollars are protected. Clearly, the
government is taking the steps to ensure that the limited public health-care
dollars are spent properly.
    "The innovative companies that are members of Rx&D, and their 20,000
employees, must abide by a strict and mandatory Code of Ethical Practices to
ensure all interactions with health care professionals meet the highest
standards. Our Code forbids giving gifts or other inducements to gain
influence with health-care professionals. We take pride in our Code because it
is the basis for building partnerships based on integrity and trust with all
governments and health stakeholders.
    "As the community that develops medicines and vaccines that improve and
save lives, we are working in partnership with the Ontario government at all
levels to ensure the integrity and transparency of the drug delivery system."

    About Rx&D

    Rx&D is an association of leading research-based biopharmaceutical
companies dedicated to improving the health of all Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 20,000 men and women working for 50 member companies and invests
more than $1 billion in research and development each year to fuel Canada's
knowledge-based economy. Guided by our Code of Ethical Practices, our
membership is committed to working in partnership with governments, healthcare
professionals and stakeholders in a highly ethical manner.




For further information:

For further information: François Lessard, Communications, (613)
236-0455, flessard@canadapharma.org

Organization Profile

Canada's Research-Based Pharmaceutical Companies (Rx&D)

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890